STOCK TITAN

Immix Biopharma Inc - IMMX STOCK NEWS

Welcome to our dedicated news page for Immix Biopharma (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immix Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immix Biopharma's position in the market.

Rhea-AI Summary
ImmixBio presents positive clinical data for NXC-201 in AL Amyloidosis, showing a 100% overall response rate and 67% complete response rate in heavily pre-treated patients. Best responder had a duration of response of 19.2 months. ImmixBio plans to submit a BLA for FDA approval. One-time treatment with NXC-201 could be an attractive alternative to current therapies, potentially restoring quality of life. NXC-201 has a uniquely favorable CAR-T tolerability profile and the ability to clear disease-causing amyloid chains from the body. No major adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
-
Rhea-AI Summary
Immix Biopharma announces positive clinical data for NXC-201 in multiple myeloma, including a 95% overall response rate and 12.9 months median progression-free survival. The therapy shows potential in BCMA-exposed patients and plans to submit a BLA for FDA approval. Safety data suggest reduced hospitalization and cost savings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.61%
Tags
-
Rhea-AI Summary
Immix Biopharma receives FDA Orphan Drug Designation for NXC-201 in the treatment of Amyloid Light Chain (AL) Amyloidosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
Rhea-AI Summary
Immix Biopharma successfully completes 2nd CAR-T NXC-201 engineering batch, supporting expansion of NEXICART-1 clinical trial to the US. Plans to expand into earlier lines of therapy and beyond 5% of US hospitals that offer CAR-T. NXC-201 shows zero neurotoxicity and favorable tolerability profile. CAR-T therapies generate over $3 billion in annual sales, NXC-201 aims to overcome side effects and expand into the remaining 95% of the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.15%
Tags
none
-
Rhea-AI Summary
Immix Biopharma (IMMX) announces presentation of Nexcella NXC-201 clinical data at healthcare conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences
-
Rhea-AI Summary
Immix Biopharma receives FDA Orphan Drug Designation for NXC-201 in multiple myeloma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
-
Rhea-AI Summary
Dr. Landau joins Nexcella Scientific Advisory Board with extensive clinical trial experience in hematology/oncology and CAR-T therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
management
-
Rhea-AI Summary
Immix Biopharma, Inc. announced that additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis will be presented at the 20th International Myeloma Society Annual Meeting in Athens, Greece. The data will be presented in a poster titled 'Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis'. The presentation will take place on September 27-29, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
Immix Biopharma Inc

Nasdaq:IMMX

IMMX Rankings

IMMX Stock Data

72.85M
14.09M
45.91%
8.47%
1.52%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Los Angeles